Patent · US Active

Pharmaceutical preparation for treating benign prostatic hyperplasia

US8231870B2 · kind B2 · utility

1Cited by

0References

11Claims

0Family size

Assignee

Volopharm GmbH · AT

Inventors

Lucia Desser · Wien, AT
Bernhard Lotz · Leonding, AT
Thomas Mohr · Jena, DE

Key dates

Filing date	Dec 3, 2008
Grant date	Jul 31, 2012
Priority date	—
Expiry date	May 29, 2029

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to the use of at least one protease for the manufacture of a medicament for the treatment and/or prevention of benign prostate hypertrophy/hyperplasia, wherein the medicament is adapted for enteral administration, the at least one protease is selected from the group consisting of plant, non-mammalian animal and microbial proteases and the at least one protease is administered in an amount of 1 to 100 mg/kg body weight.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.